NIKKEI 225
38,702.61 -152.76 (-0.39%) HANG SENG
18,577.83 -243.33 (-1.29%) CRUDE OIL
80.14 +0.31 (+0.39%) GOLD FUTURES
2,357.90 +1.40 (+0.06%) DOW
38,852.86 -216.74 (-0.55%) Bitcoin GBP
53,675.20 -131.96 (-0.25%)
EDAP TMS S.A. (EDAP)
| Previous close | 6.12 |
| Open | 6.04 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.74 - 6.14 |
| 52-week range | 3.60 - 10.32 |
| Volume | |
| Avg. volume | 40,383 |
| Market cap | 217.057M |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
EDAP to Present at the Jefferies Global Healthcare Conference
LYON, France, May 22, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 5-6, 2024, in New York City. Presentation details: Date:Wednesday, June 5thTime:7:30 AM ET Webcast:https://wsw.com/webcast/jeff302/edap/1814176 The live and archived webcas
- GlobeNewswire
EDAP Reports First Quarter 2024 Financial Results
Strong Q1 2024 U.S. Focal One® HIFU procedure growth of +92% year-over-year Q1 2024 HIFU revenue of EUR 5.8 million ($6.3 million USD), an increase of 10.2% over Q1 2023Q1 2024 total revenue of EUR 14.9 million ($16.1 million USD) increased 0.8% over Q1 2023Company to host conference call and webcast today, May 16th, at 8:30 a.m. EDT LYON, France, May 16, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the fir
- GlobeNewswire
EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting
Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the HIFU-treated arm versus 86.2% in patients who underwent radical prostatectomy (RP) Functional evaluation criteria show better results with respect to urinary continence and erectile function in patients receiving HIFU therapy versus patients receiving RP Final study results were presented during a plenary session of the AUA focused on paradigm-shifting and practice-changing c
